Abstract
INTRODUCTION
Hepatitis B infection is a life-threatening disease caused by hepatitis B virus (HBV), which attacks liver. An estimated 350 million people are infected with hepatitis B chronically worldwide, which makes it a major global health problem [1] . According to WHO, more than 780000 people die of cirrhosis and hepatocellular carcinoma (HCC) caused by chronic hepatitis B (CHB). Currently, immune modulators such as interferon-α (IFNα) or pegylated interferon-α (PEG-IFNα) and antiviral agents such as nucleotide analogues (NAs) are two approved treatments for CHB patients [2] . Compared with NAs treatment, IFNα is less likely to develop drug resistance and its finite duration is an attractive treatment strategy for CHB patients. IFNα treatment showed high rates of off-therapy host immune control over HBV and increased rates of hepatitis B e antigen (HBeAg)/hepatitis B surface antigen (HBsAg) loss or seroconversion over time [3] . However, the fact that only 30%-40% patients benefit from the IFNα therapy is still an obstacle in CHB management [4] . Therefore, it is necessary to discover predictors for outcomes of IFNα treatment to improve the personalized therapy for CHB patients. Several host and virus factors such as gender, serum HBV DNA level and alanine aminotransferase (ALT) level are considered to have influence on IFNα efficiency, but they are weak at predicting responses at individual level [5] . More and more researches have shown that host genetic factors may play an important role in the response to IFNα treatment. Single nucleotide polymorphisms (SNPs) located on IL28B are reported to affect the response to IFNα based therapy for CHB patients [6] [7] [8] . Polymorphisms on HLA-DP and IRF5 are also associated with IFNα treatment efficiency [9, 10] . It is also reported that genetic variants on STAT4 influenced the response of IFNα among CHB patients [11] . All the evidences indicate genetic variations on genes involved in immune response or IFNα signaling may lead to different clinical outcomes of IFNα therapy.
After virus infection, the expression of virusresponsive genes and antiviral cytokines such as type I interferon are induced to limit virus replication and modulate adaptive immune response. Interferonstimulated genes (ISGs) are a subset of genes response to RNA-or DNA-virus infection or type Ⅰ IFN treatment, hepatitis B (CHB) patients were enrolled in the study. All of these patients received IFNα treatment for a course of 48 wk, and were followed up for 24 wk after the treatment was end. Clinical information about virological response, hepatitis B e antigen (HBeAg) seroconversion rate and combined response at the end of the treatment, as well as the sustained response by the time of following up 24 wk after the treatment, was collected. Four tag-single nucleotide polymorphisms (SNPs) of IFIT1 were selected and assessed for their association with these clinical outcomes. Core tip: Interferon-α (IFNα) is the first line treatment for chronic hepatitis B virus (HBV) infection (CHB). However, its efficiency differs and biomarkers for predicting responses of IFNα are needed. The current study performed an epidemiologic study to investigate the association between Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1 ) polymorphisms and clinical responses of IFNα treatment in newly diagnosed chronic HBV infection patients among Chinese population. We identified that IFIT1 polymorphism rs303218 could be a predictor for the end point virological response of IFNα therapy. The finding may provide insight to the potential role of IFIT1 in the individualized and they are mainly induced by IFN-α/β [12] . Under basal condition, ISGs are not expressed in most cell types. But they can be induced immediately to a high level after virus infection or IFN treatment [13] . Their products take on diverse roles such as enhancing innate immune capabilities, inhibiting virus infection and negatively regulating signaling through the JAK-STAT pathway [14] . Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) which is an effector molecule in antivirus pathways, locates in the cytoplasm. It is an important member of ISGs family which lacking enzymatic domains or activity. Tetratricopeptide repeats (TPR) motif mediates protein-protein interaction. Proteins containing TPR motifs regulate cell cycle, transcription, protein transport and protein folding, which enable IFIT1 to serve as an effector molecule on virus replication during responses to viral infections [15] . IFIT1 is induced within two hours of exogenous IFN-α treatment [16] . It is reported that IFIT1 acts as an important innate immune bottleneck which shows positive regulation on downstream genes [17] . High level of type Ⅰ IFN is observed in IFIT1-expressing cells [18] .
RESULTS

At
Researches have indicated that the antiviral activity of IFIT1 is modulated by 2'-O methylation of viral RNA. Abrogation of 2'-O methylation resultes in enhanced type Ⅰ IFN and IFIT1 sensitivity [19] [20] [21] . IFIT1 can sense the methylation state of capped RNA and inhibit viruses by binding to their 5' cap structure that lack 2'-O methylation [22, 23] . It can also sense viral RNA by recognizing uncapped 5'-ppp and stop it from actively replicating [24] . Despite sensing 2'-O methylation viral RNA, IFIT1 also exerts its antivirus function through inhibiting steps in translation initiation. It is reported that IFIT1 reduces the translation efficiency by binding to the subunits of eIF3 complex, which functions in several steps in translation initiation [25, 26] . IFIT1 is also responsible for IFN-induced alteration of virus transcription and protein synthesis [27] . Silencing of IFIT1 leads to remarkable increased HBV replication, which indicates that IFIT1 plays an important role in the regulation of HBV transcription and posttranscriptional procedure [28] . All the evidences indicate that IFIT1 is an important effector in both virus infection and IFNα treatment. It has been reported that IFIT1 acts as a potential biomarker for Peg-IFNα treatment efficiency in hepatitis C virus (HCV) patients [29] . However, few researches mention about IFIT1's role in HBV infected patients who treated with IFNα. To illuminate whether IFIT1 related to IFNα treatment efficiency for CHB, we conducted an association study that assessed the relationship between tag-SNPs on IFIT1 and clinical outcomes of IFNα treatment among 225 Chinese CHB patients.
MATERIALS AND METHODS
Patient recruitment
Patients enrolled in this study were newly diagnosed 
SNP selection and genotyping
IFIT1 is about 13.9 kb long and locates on chromosome 10q23.31. To investigate the association between IFIT1 and IFNα treatment efficiency, 4 tag-SNPs located in IFIT1 gene region were selected according to the genotype data of Han Chinese in Beijing (CHB) population from the phase II HapMap SNP database, by software Haploview 4.1 (available at http://www. broadinstitute.org/haploview). The thresholds for tag-SNP selection were defined as 0.8 for correlation coefficient and a cutoff of 0.2 for MAF. Blood sample were collected at the time of recruitment. Genome DNA was extracted by salt-out method. All the selected SNPs were genotyped using DNA sequencing on illumine Miseq high throughout sequencing platform. Random duplicate sample were performed and all the two-sided, and P < 0.05 was considered statistically significant. All the statistical analyses were performed by SPSS (version 15.0; SPSS Inc., Chicago, Ill).
RESULTS
Patient characteristics and clinical outcomes
225 CHB patients who met the recruitment criterion were included in the study to investigate the association between IFIT1 polymorphisms and IFNα treatment responses. Table 1 Table 3 , the level of baseline ALT was associated with HBeAg seroconversion (P = 0.020), and the distribution of combined response was significantly different between male and female patients (P = 0.027). HBV genotype exhibited significant association with all the clinical outcomes including virological response (P = 0.012), HBeAg seroconversion (P = 0.001), combined response (P = 0.038) and sustained response (P = 2.37 × 10 -4 ). Other clinical characteristics including age, baseline AST and baseline HBV DNA level, showed association with none of the clinical outcomes.
IFIT1 polymorphisms and IFNα treatment's virological response
All the SNPs were evaluated for their association with IFNα treatment efficiency, including the end point responses and sustained response. It was considerable that none of the IFIT1 SNPs' allele frequency showed distribution differences in HBeAg seroconversion, combined response or sustained response (data not shown), but all of them had significantly different allele frequency distribution among patients who achieved virological response (Table 4) . So we further assessed these SNPs' association with virological response samples were concordant with the genotyping results. All SNPs were in Hardy-Weinberg equilibrium (P > 0.001). More details about these four tag-SNPs were shown in Supplementary Table 1.
Statistical analysis
Factors that had P value < 0.05 were regarded as covariates (Table 2) . Univariable logistic regression analysis was performed to assess allele frequency distribution of IFIT1 SNPs in different patient groups. Chi-square test and unconditional logistic regression adjusted for covariates were used to assess whether IFIT1 SNPs' genotypes had statistically significant difference in the distribution of clinical outcomes, and to estimate the association between efficiencies and SNPs by OR and in additive, dominant, recessive or codominant model. Stratified analysis was performed to investigate significant SNPs' effects in different subgroups. All P values reported in this study were 
DISCUSSION
IFNα or PEG-IFNα is the first-line treatment for Chronic HBV infection. It can maintain high rates of off-therapy host immune control over HBV. However, IFNα therapy gives benefits to only 30%-40% CHB patients, which suggests the necessity for discovering efficiency predictors for IFN treatment to improve the personalized therapy for CHB patients. It is reported that female patients, higher ALT level and lower serum HBV DNA level may indicate a better IFNα response [30] . But all of these host or virus factors are not ideal predictors at individual level. Researchers expect that biomarkers that rely on the basis of patients' genetic background can highlight the road to personalized medicine. As one of the key components of IFNα induced pathways, IFIT1 is indispensable for IFNα to eliminate HBV. However, few researches focused on its role in HBV management, especially its pharmacogenetic effects. In this study, we investigated whether IFIT1 gene polymorphisms could predict IFNα treatment efficiency among Chinese CHB patients. The results showed that rs303218 was associated with end point virological response after 48 wk IFNα therapy. Patients who carried GG genotype of rs303218 achieved higher rate of virological response when compared to GA/AA genotype.
IFNα is an important innate immune response cytokine which acts as the first line defense of HBV infection [31] . Patients who have CHB may have reduced ability of producing IFNα, but they show response to exogenous IFNα and then induce ISGs expression to activate related signaling to inhibit HBV replication [32, 33] . The function of ISGs includes enhancing innate immune capabilities and inhibiting virus infection. IFIT1 is one of the most immediately induced ISGs after exogenous IFNα treatment. The most well-known function of IFIT1 is that it can sense and recognize the 2'-O unmethylated RNA and block the translation of viral RNA lacking 2'-O methylation [22, 34] . It can also recognize the uncapped 5'-ppp and stop it from actively replicating [35] . But viruses that using cellular RNA polymerase II to synthesize their mRNA may escape the IFIT1-mediated restriction [36] . However, there are other ways that IFIT1 exerts its anti-virus function. For example, IFIT1 acts as an important modulator in virus transcription and replication. It can inhibit cap-dependent protein synthesis by binding to the subunits of translation initiation complex elF3 [25, 37] . Researches has demonstrated that IFIT1 can restrict HCV growth by inhibiting HCV replication, and the expression level of IFIT1 can be potential biomarker of response to IFNα in patients with HCV [29, 38] . IFIT1 restricts the translation and replication of many other viruses such as HPV, HIV and alphavirus, and promotes the induction of IFNα to enhance immune response [18, 39, 40] . All these evidences demonstrate [28] . Our findings indicated that rs303218 was associated with virological response, which also suggested IFIT1's indispensable role in controlling HBV replication.
As we know that, the polymorphism of rs303218 locates in the intron region of IFIT1. Other than causing missense mutation which results in protein dysfunction, intronic polymorphisms may locate in the regulatory element sites, such as splice donor, acceptor, or cis-regulatory element region, which means they might regulate cell metabolism through modulating mRNA splicing and gene expression patterns [41] [42] [43] . NCBI database shows that IFIT1 has three isoforms. They are different from each other by their different alternate initiation translation site. A reasonable conjecture is that different IFIT1 isoform may have different affinity to IFIT family members or to the translation initiation complex such as elF3, or they may display different capability of recognizing 2'-O unmethylated RNA or uncapped 5'-ppp. However, no evidence was found to support that variants on IFIT1 facilitated gene splicing or gene expression. A recent research showed that a variant known as rs304478, which located within 2 kb upstream of IFIT1, was an independent predictive factor for pegylated-IFN therapy in HCV patients [44] . Although rs304478 was not included in the present study due to its relative lower MAF in Chinese population, it highlighted a fact that IFIT1 could be potential biomarker for IFNα treatment efficiency. Another assumption is that the real reason affecting IFIT1 mRNA stability or protein synthesis, is the effective SNPs which are in linkage disequilibrium with rs303218. Nevertheless, all these are just hypothesis that need more researches to discover the real facts of how IFIT1 intronic SNPs influence IFNα treatment efficiency, and it is necessary to find the actual genetic variations that affect responses of IFNα.
In conclusion, the study investigated the association between IFIT1 polymorphisms and clinical outcomes of IFNα treatment for CHB patients among Chinese population. The results provided evidences for IFIT1's part in IFNα treatment efficiency. Our study highlights the potential role of IFIT1 in predicting IFNα treatment's end point virological response, although the exact mechanism needs to further investigate. The findings needs to be validated in an independent cohort to further illuminate the effects of IFIT1's variants for IFNα therapy. And it is meaningful to assess IFIT1's predicting potential in different ethnicities.
Function studies are needed to explore the mechanism between IFIT1 and IFNα therapy.
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